Yet, in cases of serious COVID-19 with pneumonia and acute respiratory distress syndrome (ARDS), tocilizumab, a humanized monoclonal Interleukin-6-receptor antagonist, is administered in a phase II open label clinical trial (NCT04317092) to supress hyperinflammation that is assumed to cause fatal lung and multiorgan injury 6,7. This evidence concerns the gene IL6R and COVID-19.